ACCS Composition Reduces Vascular Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and conditions characterized by increased vascular permeability, such as viral hemorrhagic fevers, are limited and lack a universal, effective solution to reduce abnormal vascular permeability.
Innovation Solution
Administration of novel cellular factor-containing solution compositions, specifically Amnion-derived Cellular Cytokine Solution (ACCS), which contains over 200 proteins, cytokines, and growth factors, to modulate vascular permeability and restore it to a homeostatic state.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional treatments are used for diseases with increased vascular permeability, then treatment coverage is limited, but the complexity of finding effective treatments increases
Solution Approach 1:
The patent applies universality by developing a single therapeutic agent (ACCS composition) that can treat multiple diseases and conditions characterized by increased vascular permeability, including viral hemorrhagic fevers, sepsis, ARDS, and other inflammatory conditions. This multi-functional approach resolves the contradiction by providing broad treatment coverage through one versatile therapy rather than requiring multiple disease-specific treatments.
2Reliability
If ACCS is administered to reduce vascular permeability, then vascular permeability decreases, but the mechanism involves multiple proteins and cytokines making the composition complex
Solution Approach 1:
The patent applies composite materials by formulating ACCS as a complex composition containing over 200 different proteins, cytokines, and growth factors that work synergistically to reduce vascular permeability. This composite approach resolves the contradiction by combining multiple active components into a single therapeutic formulation that achieves reliable治疗效果 through the coordinated action of numerous biomolecules.
Solution Approach 2:
The patent applies self-service by utilizing the natural biological components (proteins, cytokines, growth factors) that are already present in amnion-derived cellular factor-containing solutions to achieve the therapeutic effect. The composition leverages endogenous biological mechanisms rather than requiring external administration of multiple separate agents, thereby achieving reliable vascular permeability reduction through a self-contained formulation.
3Speed
If mast cells release agents to trigger inflammatory response, then vascular permeability increases rapidly, but this rapid response causes edema formation and tissue damage
Solution Approach 1:
The patent applies preliminary anti-action by administering ACCS composition that contains anti-inflammatory cytokines and proteins which counteract the harmful effects of mast cell-mediated vascular permeability increase before significant edema and tissue damage can occur. The composition proactively addresses the pathological processes triggered by rapid inflammatory responses, neutralizing harmful effects while preserving the beneficial aspects of the immune response.
Data Source
AI summary
The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).